Prosecution Insights
Last updated: April 19, 2026
Application No. 17/785,979

PROCESS FOR THE PRODUCTION OF MYCOPROTEIN

Non-Final OA §103§112
Filed
Jun 16, 2022
Examiner
MONSHIPOURI, MARYAM
Art Unit
1651
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
3F Bio Ltd.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
756 granted / 956 resolved
+19.1% vs TC avg
Strong +37% interview lift
Without
With
+37.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
28 currently pending
Career history
984
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
23.9%
-16.1% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
36.3%
-3.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 956 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response to restriction letter of 10/9/25 is acknowledged. Applicant elected Group I and species 3, only, without traverse. Claims 3-4, 8-9, 12-15, 21-27 and the following species :1-2, 4-6, are hereby withdrawn as drawn to non-elected subject matter. Claims 6-7, 11 and 19-20 are canceled. DEATLED ACTION Claims 1-2, 5, 10, 16-18, 28-29 are under examination on the merits. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-2, 5, 10, 16-18, 28-29 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In claim 1 (and its dependent claims 2, 5, 10, 16-18, 28-29) it is unclear what is being fermented. Further in claim 28, it is own right, applicant has mentioned that “a microorganism” is being fermented but failed to explain what specific microorganism(s) is referred to. Claims 2, 5, 10, 16-18 and 29 are merely rejected for depending from base claim 1. Claims 16-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In claims 16-17, the term “substantially” is confusing. It is unclear how much or what parentage constitutes “substantially”. Applicant has not specifically defined said term in the disclosure and in page 12, mentions that “the term “substantially solid phase” is meant solid-rich phase and the term “substantially liquid phrase” is meant liquid-rich phase”. But said definitions are also ambiguous because it is unknown how much or what percentage of solids or liquids result in “solid-rich phase” and liquid -rich phase”, respectively. Appropriate clarification is required. Claims 16-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In dependent claims 16-17, it is unclear if “the step of isolating ….” is the first isolation step or the second isolation step. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-2, 5, 10, 16-18, 28-29 are rejected under 35 U.S.C. 103 as being unpatentable over Fazenda et al., “Fazenda” (US2017/0226,551, 10/2017). Fazenda teaches and claims (see claim 20) an integrated aerobic method or system for the co-production of mycoprotein and ethanol from a feedstock (such as cereal) material, the method comprising the steps of: a) providing an aqueous fermentable broth comprising one or more cereal materials; b) fermenting at least a portion of the aqueous fermentable broth (fresh broth) with a micro-organism(s) in order to obtain mycoprotein or ethanol respectively and partially fermented broth (wherein said” partially fermented” broth is inherently partially spent media, see also [0025], where “partially fermented” broth is referred to an initial fermentation broth that has undergone an initial fermentation in order to produce mycoprotein”. Obviously, the resulting media of such initial fermentation will be “partially spent”); c) separating the mycoprotein or ethanol from the partially fermented broth; d) fermenting at least a portion of the partially fermented broth, optionally with a portion of unfermented aqueous fermentable broth, with a micro-organism(s) in order to obtain ethanol or mycoprotein respectively and a spent fermentation residue; and e) isolating the ethanol or mycoprotein from the spent fermentation residue. Applicant is reminded that in step (d) above, a portion of “partially fermented broth” mixed with the “aqueous fermentation media” inherently requires reintroduction (recycling) of isolated partially fermented broth separated and isolated from mycoprotein or ethanol in step (c) into the fermentation vessel, said vessel comprising said aqueous fermentation media. Obviously, such reintroduction, will decrease the amount of fermentation media required for the whole process. In [0038], according to Fazenda, “once fermentation is completed, the mycoprotein and spent fermentation broth may be subjected to a heat treatment in order to remove/destroy nucleic acid, such as RNA, which may be present. Therefore, according to said paragraph, heating is performed prior to (before) mycoprotein isolation from the spent fermentation media/ mycoprotein mixture. In said same paragraph, Fazenda states, “The mycoprotein may then be separated/isolated from the spent fermentation broth, using methods such as centrifugation or filtering, for example, and then dried.” Such dried mycoprotein will be “substantially” (see 112 second rejection above) solid phase (resulting in mycoprotein in solid phase” and since partially spent fermentation media was not dried ; it will be in “substantially” liquid phrase inherently comprising nutrients and carbohydrates. Therefore, it is believed the teachings of Fazenda, as a whole, render this invention obvious. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARYAM MONSHIPOURI whose telephone number is (571)272-0932. The examiner can normally be reached full-flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Weidner can be reached at 571-272-3045. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARYAM MONSHIPOURI/Primary Examiner, Art Unit 1651
Read full office action

Prosecution Timeline

Jun 16, 2022
Application Filed
Oct 29, 2025
Examiner Interview (Telephonic)
Oct 31, 2025
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12584150
ENDOGENOUS LIPASE FOR METAL REDUCTION IN DISTILLERS CORN OIL
2y 5m to grant Granted Mar 24, 2026
Patent 12577572
COMPOSITIONS, SYSTEMS, AND METHODS FOR HIGH LEVEL EXPRESSION OF RECOMBINANT PROTEIN
2y 5m to grant Granted Mar 17, 2026
Patent 12577571
Mutant Dnase1L3 with Improved Serum Half-Life
2y 5m to grant Granted Mar 17, 2026
Patent 12565669
OPTIMIZED PROCESS FOR PRODUCING SECOND-GENERATION SUGARS AND FERMENTATION PRODUCTS
2y 5m to grant Granted Mar 03, 2026
Patent 12559782
FUNGAL STRAINS COMPRISING ENHANCED PROTEIN PRODUCTIVITY PHENOTYPES AND METHODS THEREOF
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+37.3%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 956 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month